Janus Henderson Global Life Sciences C (JFNCX)
56.86
+0.05
(+0.09%)
USD |
Mar 30 2023
Key Stats
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 1.76% | 4.530B | 0.00% | 21.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -11.27M | -1.27% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | JNGLX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Janus Henderson |
| Prospectus Benchmark Index | |
| MSCI World/Health Care NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Andrew Acker | 15.84 yrs |
| Daniel Lyons | 0.08 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
44
-11.27M
-2.719B
Category Low
6.230B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of February 28, 2023
Risk
Performance Versus Category
As of March 29, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of March 29, 2023.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| UnitedHealth Group Inc | 6.56% | 469.96 | 0.72% |
|
AstraZeneca PLC
|
4.39% | -- | -- |
| AbbVie Inc | 3.90% | 157.90 | -0.06% |
| Merck & Co Inc | 2.99% | 105.91 | 0.94% |
| Eli Lilly and Co | 2.98% | 340.69 | 1.44% |
| Novartis AG ADR | 2.69% | 91.57 | 1.53% |
| Sarepta Therapeutics Inc | 2.60% | 135.96 | -0.44% |
|
Sanofi SA
|
2.59% | -- | -- |
| Abbott Laboratories | 2.34% | 99.08 | 0.47% |
| Thermo Fisher Scientific Inc | 2.33% | 563.08 | 1.43% |
Basic Info
| Investment Strategy | |
| The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | JNGLX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Janus Henderson |
| Prospectus Benchmark Index | |
| MSCI World/Health Care NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Andrew Acker | 15.84 yrs |
| Daniel Lyons | 0.08 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (3-29-23) | 0.00% |
| 30-Day SEC Yield (8-31-17) | Upgrade |
| 7-Day SEC Yield (12-18-12) | Upgrade |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 23.52 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of December 31, 2022
Fund Details
| Key Dates | |
| Inception Date | 7/6/2009 |
| Last Annual Report Date | 9/30/2022 |
| Last Prospectus Date | 1/27/2023 |
| Share Classes | |
| JAGLX | Other |
| JFNAX | A |
| JFNIX | Inst |
| JFNNX | N |
| JFNSX | S |
| JNGLX | D |
| Attributes | |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |